Physician profile
Daniel Grobman
NPI 1588680821
$922.24
in general payments reported to CMS, 2019-2025
15 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.59 · 2020: $20.13 · 2022: $249 · 2023: $237 · 2024: $75.51 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $528.56 | 2022-2025 | Proclaim |
| Ferring Pharmaceuticals INC. | $54.48 | 2019 | |
| Emd Serono, INC. | $46.57 | 2023 | Mavenclad |
| Microtransponder, INC. | $36.88 | 2024 | |
| Mml US, INC. | $35.23 | 2025 | Reactiv8 |
| Livanova USA, INC. | $33.53 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Relievant Medsystems, INC. | $31.59 | 2019 | |
| Argenx US, INC. | $28.57 | 2023 | Vyvgart |
| Janssen Biotech, INC. | $25.05 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.99 | 2022 | |
| Aquestive Therapeutics, INC. | $20.13 | 2020 | |
| Neurocrine Biosciences, INC. | $16.90 | 2023 | Ingrezza, Ongentys |
| Piramal Critical Care | $14.96 | 2023 | |
| Avanos Medical | $14.28 | 2024 | Standard Rf Disposables |
| Medtronic USA, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Grobman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.